45
report
Learning from COVID-19: Reimagining Public-Private Partnerships in Public Health
The Milken Institute Center for Public Health leveraged our network of thought leaders to maximize
learnings from the COVID-19 pandemic, focused on examining the private sector’s role and responsibility in supp
+ Read More
report
Strengthening the Biomedical Innovation Ecosystem: A Scorecard for System Assessment
As patients, we often evaluate our interactions within the "system" of biomedical innovation with a
simple question: "Did it work for me?" This evaluation considers many issues, including whether the best treatments are accessible and available, how the
+ Read More
report
Cell and Gene Therapies: Looking Ahead to 2022
Cell and gene therapies are a new category of medicines transforming how we treat and potentially c
ure disease. Both cell and gene therapies seek to modify genetic material to fight disease.
+ Read More
report
State Technology and Science Index 2014
Massachusetts is first – once again – in the Milken Institute’s State Technology and Science Index
2014.
+ Read More
report
State Technology and Science Index 2020
The State Technology and Science Index (STSI) provides a benchmark for evaluating the knowledge eco
nomies of all 50 US states.
+ Read More
report
State Technology and Science Index 2016: Sustaining Americas Innovation Economy
As the Great Recession recedes in our rearview mirrors, it is becoming ever more apparent that inno
vative activities are determining an increasing proportion of the long-term economic growth of cities, metropolitan areas, regions, states, and even natio
+ Read More
report
State Technology and Science Index 2012
Massachusetts is first -- again -- in the Milken Institute's State Technology and Science Index 201
2.
+ Read More
report
State Technology and Science Index 2016: California Perspectives
The Milken Institute’s State Technology and Science Index (STSI) series benchmarks states
on their science and technology capacity.
+ Read More
report
Policy Issue Brief: A Call to Action for Diversity in Clinical Trials
FasterCures has initiated a body of work to advance system change within biomedical research to foc
us on and value diversity and representation within clinical trials.
+ Read More
report
Roadmap for Investment in Dementia Care
On average, people with Alzheimer’s disease and frontotemporal dementia live six to ten years after
diagnosis. People with vascular dementia and Lewy body dementia live on average five to six years after diagnosis.
+ Read More
report
A Global Early Warning System for Pandemics: A Blueprint for Coordination
The COVID-19 pandemic has had enormous health, social, and economic consequences.
report
Models for Financing Antibiotic Development to Address Antimicrobial Resistance
The Financial Innovations Labs® and FasterCures teams have collaborated on a project to id